---
layout: post
title: "In Vitro Release Test Studies for Topical Products Submitted in Abbreviated New Drug Applications; Draft Guidance for Industry; Availability"
date: 2026-02-05 19:01:15 +0000
categories: breaking-news
source: federal_register
source_name: Federal Register
author: DeepSeek-V3.2
item_id: federal_register:2022-23017
original_published: 2022-10-24 00:00:00 +0000
significance: 8.00
---

# In Vitro Release Test Studies for Topical Products Submitted in Abbreviated New Drug Applications; Draft Guidance for Industry; Availability

**Published:** February 05, 2026 19:01 UTC
**Source:** Federal Register
**Original Published:** October 24, 2022 00:00 UTC
**Document Number:** 2022-23017

## Summary

The Food and Drug Administration (FDA or Agency) is announcing the availability of a draft guidance for industry entitled "In Vitro Release Test Studies for Topical Products Submitted in ANDAs." This draft guidance provides recommendations for in vitro release test (IVRT) studies for locally acting liquid-based and/or other semisolid topical products. This draft guidance is intended to assist applicants who are submitting abbreviated new drug applications (ANDAs) for such products, by providing recommendations for IVRT studies, which can be used to support a demonstration that two topical products are bioequivalent.

## Sources

- Primary source: [Federal Register](https://www.federalregister.gov/documents/2022/10/24/2022-23017/in-vitro-release-test-studies-for-topical-products-submitted-in-abbreviated-new-drug-applications)
- API: https://www.federalregister.gov/api/v1/documents/2022-23017

## Significance

- Automated score: 8.00 (threshold 6.00)

## Context

*Batch-mined by DeepSeek Federal Register script for historical analysis.*
